Identification of Molecularly Targeted Therapy-Induced Immunopeptidome in Diffuse Midline Glioma (DMG)

ABSTRACT: We used MHC-I immunopeptidomics to study how MTX-241F, a selective EGFR/PI3K inhibitor, alters antigen presentation in diffuse midline glioma (H3K27M) and glioblastoma xenografts. MHC-I–bound peptides from vehicle- and drug-treated tumors were profiled by LC–MS/MS to identify tumor- and treatment-specific peptides, including candidate brain-enriched biomarkers and immunotherapy targets.

INSTRUMENT(S):

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Brain, Permanent Cell Line Cell

DISEASE(S): Glioblastoma,Diffuse Midline Glioma

SUBMITTER: Habeebah Owolabi  

LAB HEAD: Stefanie Galban

PROVIDER: PXD070941 | Pride | 2026-02-10

REPOSITORIES: Pride